OmicsBank raises $2.25M to move overseas patient data to biopharma
What's the deal? OmicsBankDealroom has a profile for this one. Try Dealroom →, a San Francisco-based clinical data infrastructure startup, has raised $2.25 million in seed funding from Redesign Health. The company connects fragmented hospital data across overseas markets for drug development and healthcare AI.
What's the endgame? OmicsBank's platform lets hospitals standardise and de-identify clinical narratives and data at the source. It ingests records, imaging, pathology, and genomics into datasets for drug discovery, clinical AI model training, biomarker discovery, and real-world evidence studies.
The scale: Founded in 2025 by Sumit Sinha and Vijay Goel, OmicsBank operates across more than 90 hospitals and diagnostic labs in South Asia, Southeast Asia, and the Middle East. Its network spans longitudinal EHR data from 12.5 million patients, over 30 million DICOM images, 6 million pathology slides, and 500,000 genome sequences.
What's the money for? OmicsBank plans to expand across US health systems, pharmaceutical and biotech companies, contract research organisations, and AI developers. It will also grow its clinical data network across Asia and the Middle East, add hospital partners, and build GPU-enabled research environments.
The signal: As AI reshapes drug discovery, a growing number of health tech companies are betting that access to standardised patient data is the bottleneck worth solving. OmicsBank's wager is that datasets from underused overseas hospital networks can feed the models and studies now driving biopharma.
Read more: endpoints.news, finsmes.com
Image credit: Generated with Gemini
